Current and emerging pharmacotherapies for obesity in Australia

Haby, 2012, Future predictions of body mass index and overweight prevalence in Australia, 2005-2025, Health Promot Int, 27, 250, 10.1093/heapro/dar036 Korda, 2015, The relationship between body mass index and hospitalisation rates, days in hospital and costs: findings from a large prospective linked data study, PLoS One, 10, e0118599, 10.1371/journal.pone.0118599 AMA. Recognition of Obesity as a Disease. Available from: http://www.npr.org/documents/2013/jun/ama-resolution-obesity.pdf. [Accessed 30 May 2017]. WHO, 1998 ANZOS. The Australian and New Zealand Obesity Society management algorithm. Available at: http://anzos.com/assets/Obesity-Management-Algorithm-18.10.2016.pdf. [Accessed 30 May 2017]. Pi-Sunyer, 2009, The medical risks of obesity, Postgrad Med, 121, 21, 10.3810/pgm.2009.11.2074 Global BMI Mortality Collaboration, 2016, Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents, Lancet, 388, 776, 10.1016/S0140-6736(16)30175-1 Summary guide for the management of overweight and obesity in primary care. https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/n57b_obesity_guidelines_summary_guide_131219.pdf. Curioni, 2005, Long-term weight loss after diet and exercise: a systematic review, Int J Obes (Lond), 29, 1168, 10.1038/sj.ijo.0803015 Westerveld, 2016, Through thick and thin: identifying barriers to bariatric surgery, weight loss maintenance, and tailoring obesity treatment for the future, Surg Res Pract, 8616581 Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512 Ioannides-Demos, 2011, Pharmacotherapies for obesity: past, current, and future therapies, J Obes, 2011, 179674, 10.1155/2011/179674 Secher, 2014, The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss, J Clin Invest, 124, 4473, 10.1172/JCI75276 Roepke, 2012, Serotonin 5-H T2C receptor-mediated inhibition of the M-current in hypothalamic POMC neurons, Am J Physiol Endocrinol Metab, 302, E1399, 10.1152/ajpendo.00565.2011 Faith, 2006, Social environmental and genetic influences on obesity and obesity promoting behaviors: fostering research integration, 236 Sumithran, 2011, Long-term persistence of hormonal adaptations to weight loss, N Engl J Med, 365, 1597, 10.1056/NEJMoa1105816 FDA, 2012 European Medicines Agency, 2014 Hartmann, 1993, Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake, Br J Clin Pharmacol, 36, 266, 10.1111/j.1365-2125.1993.tb04228.x Kopelman, 2010, Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical), Obesity (Silver Spring), 18, 108, 10.1038/oby.2009.155 Torgerson, 2004, XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients, Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 Weintraub, 1984, A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination, Arch Intern Med, 144, 1143, 10.1001/archinte.1984.00350180055008 Astrup, 2012, Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide, Int J Obes (Lond), 36, 843, 10.1038/ijo.2011.158 Pi-Sunyer, 2015, A randomized controlled trial of 30. mg of liraglutide in weight management, N Engl J Med, 373, 11, 10.1056/NEJMoa1411892 Davies, 2015, Efficacy of liraglutide for weight loss among patients with type 2 Diabetes: the SCALE diabetes randomized clinical trial, JAMA, 314, 687, 10.1001/jama.2015.9676 Wadden, 2013, Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study, Int J Obes (Lond), 37, 1443, 10.1038/ijo.2013.120 O’Neil, 2012, Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study, Obesity (Silver Spring), 20, 1426, 10.1038/oby.2012.66 Fidler, 2011, A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial, J Clin Endocrinol Metab, 96, 3067, 10.1210/jc.2011-1256 Smith, 2010, Multicenter, placebo-controlled trial of lorcaserin for weight management, N Engl J Med, 363, 245, 10.1056/NEJMoa0909809 Greenway, 2010, Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 376, 595, 10.1016/S0140-6736(10)60888-4 Apovian, 2013, A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II), Obesity (Silver Spring), 21, 935, 10.1002/oby.20309 Hollander, 2013, Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes, Diabetes Care, 36, 4022, 10.2337/dc13-0234 Gadde, 2011, Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 1341, 10.1016/S0140-6736(11)60205-5 Allison, 2012, Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP), Obesity (Silver Spring), 20, 330, 10.1038/oby.2011.330 Orlistat (Australian PI). Available at: http://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropxencp11214. [Accessed 5 May 2017]. Phentermine (Australian PI). Available at: http://www.guildlink.com.au/gc/ws/ia/pi.cfm?product=iapdurom11113. [Accessed 5 May 2017]. Novo Nordisk Pharmaceuticals Pty Limited, 2015 Lorcaserin (US PI). Available at: https://www.belviq.com/-/media/Files/BelviqConsolidation/PDF/Belviq_Prescribing_information-pdf.pdf?la=en. [Accessed 5 May 2017]. Naltrexone/bupropion ER tablets (US PI). Available at: http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&cacheRandomizer=3a174fd9-eb76-419c-abf5-c8d2582d7280. [Accessed 5 May 2017]. Phentermine/topiramate ER (US PI). Available at: https://qsymia.com/pdf/prescribing-information.pdf. [Accessed 5 May 2017]. Abenhaim, 1996, Appetite-suppressant drugs and the risk of primary pulmonary hypertension, N Engl J Med, 335, 609, 10.1056/NEJM199608293350901 van Can, 2014, Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults, Int J Obes (Lond), 38, 784, 10.1038/ijo.2013.162 Blackman, 2014, Liraglutide 3.0mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: SCALE Sleep Apnoea trial [abstract no. 184], Diabetologia, 57, S85 le Roux, 2017, 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial, Lancet, 389, 1399, 10.1016/S0140-6736(17)30069-7 Smilowitz, 2014, Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease, Circulation, 129, 2305, 10.1161/CIRCULATIONAHA.113.006985 Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 375, 311, 10.1056/NEJMoa1603827 Egan, 2014, Pancreatic safety of incretin-based drugs — FDA and EMA assessment, N Engl J Med, 370, 794, 10.1056/NEJMp1314078 Steinberg, 2017, Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 Diabetes: secondary analyses of pooled data from the SCALE Clinical Development Program, Diabetes Care, 40, 839, 10.2337/dc16-2684 Meltzer, 2013, Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs, J Clin Invest, 123, 4986, 10.1172/JCI70678 Billes, 2014, Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss, Pharmacol Res, 84C, 1, 10.1016/j.phrs.2014.04.004 Sweeting, 2014, Management of obesity and cardiometabolic risk — role of phentermine/extended release topiramate, Diabetes Metab Syndr Obes, 7, 35 EMA. Refusal of the marketing authorisation for Qsiva (phentermine/topiramate). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215.pdf. [Accessed 30 May 2017]. Halpern, 2015, Why are anti-obesity drugs stigmatized?, Expert Opin Drug Saf, 14, 185, 10.1517/14740338.2015.995088 Wing, 2011, Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes, Diabetes Care, 34, 1481, 10.2337/dc10-2415 Khera, 2016, Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis, JAMA, 315, 2424, 10.1001/jama.2016.7602